(Q34034566)

30 July 2017

title

Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study (English)

1 reference

30 July 2017

0 references

0 references

0 references

0 references

Jill P Smith

1

1 reference

30 July 2017

Douglas Field

2

1 reference

30 July 2017

Sandra I Bingaman

3

1 reference

30 July 2017

Robert Evans

4

1 reference

30 July 2017

David T Mauger

5

1 reference

30 July 2017

publication date

1 April 2013

1 reference

Journal of Clinical Gastroenterology

30 July 2017

published in

1 reference

30 July 2017

volume

47

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

339-345

1 reference

Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Defensin-barbed innate immunity: clinical associations in the pediatric population

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Low-dose naltrexone therapy improves active Crohn's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Chemokines: integrators of pain and inflammation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

A review of activity indices and end points for clinical trials in children with Crohn's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Opioid G protein-coupled receptors: signals at the crossroads of inflammation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Naloxone treatment for irritable bowel syndrome--a randomized controlled trial with an oral formulation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Centrally acting agents and visceral sensitivity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Quality-of-life measures in chronic diseases of childhood.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Opioids, opioid receptors, and the immune response

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Development of a quality-of-life index for pediatric inflammatory bowel disease: dealing with differences related to age and IBD type

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

A simple index of Crohn's-disease activity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Development and validation of a pediatric Crohn's disease activity index

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

A clinical scoring system for chronic inflammatory bowel disease in children

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

The opioid antagonist naltrexone improves murine inflammatory bowel disease

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Naltrexone and disulfiram in patients with alcohol dependence and current depression.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Narcotic use in patients with Crohn's disease.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

Enhanced analgesic potency and reduced tolerance of morphine in 129/SvEv mice: evidence for a deficiency in GM1 ganglioside-regulated excitatory opioid receptor functions

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586944

The IMPACT Questionnaire: A Valid Measure of Health-Related Quality of Life in Pediatric Inflammatory Bowel Disease

29 October 2018

1 reference

12 December 2020

Naltrexone and hepatotoxicity

1 reference

12 December 2020

Growth failure in children with inflammatory bowel disease: a prospective study

1 reference

12 December 2020

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

1 reference

12 December 2020

Study of hepatotoxicity of naltrexone in the treatment of alcoholism

1 reference

12 December 2020

Hepatosplenic T cell lymphoma in inflammatory bowel disease

1 reference

12 December 2020

Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease

1 reference

12 December 2020

10.1097/MCG.0B013E3182702F2B

Identifiers

DOI

1 reference

30 July 2017

1 reference

30 July 2017

1 reference